Alterations of the arginine metabolome in sickle cell disease a growing rationale for arginine therapy

Hematology/Oncology Clinics of North America

Volumn 28, Issue 2, 2014, Pages 301-321

  Morris, Claudia R ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Arginase; Arginine; Hemolysis; Nitric oxide; Sickle cell disease; Vasoocclusive pain episodes

Indexed keywords

ARGININE; HYDROXYUREA; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE SYNTHASE; OPIATE; ORNITHINE; PLACEBO; UREA; ANTISICKLING AGENT; HEMOGLOBIN F;

AMINO ACID METABOLISM; AMINO ACID SYNTHESIS; AMINO ACID TRANSPORT; BIOSYNTHESIS; CARDIOPULMONARY EXERCISE TEST; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; ENZYME ACTIVITY; HOMEOSTASIS; HOSPITAL DISCHARGE; HOSPITALIZATION; HOT FLUSH; HUMAN; KIDNEY DYSFUNCTION; LEG ULCER; LUNG ARTERY PRESSURE; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; METABOLOME; MORTALITY; NAUSEA; PAIN; PHARMACOKINETICS; PHASE 2 CLINICAL TRIAL (TOPIC); PRIAPISM; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SICKLE CELL ANEMIA; TREATMENT RESPONSE; UREA CYCLE; VOMITING; ANEMIA, SICKLE CELL; DRUG COMBINATION; METABOLISM; TREATMENT OUTCOME;

ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; ARGININE; DRUG THERAPY, COMBINATION; FETAL HEMOGLOBIN; HUMANS; HYDROXYUREA; METABOLOME; TREATMENT OUTCOME;

EID: 84896898737     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2013.11.008     Document Type: Review

References (138)

1. Morris C.R., Kato G.J., Poljakovic M., et al. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension and mortality in sickle cell disease. JAMA 2005, 294:81-90.
2. Morris C.R., Kuypers F.A., Larkin S., et al. Patterns of arginine and nitric oxide in sickle cell disease patients with vaso-occlusive crisis and acute chest syndrome. JPediatr Hematol Oncol 2000, 22:515-520.
3. Enwonwu C.O., Xu X., Turner E. Nitrogen metabolism in sickle cell anemia: Free amino acids in plasma and urine. Am J Med Sci 1990, 300:366-371.
4. Lopez B., Kreshak A., Morris C.R., et al. L-arginine levels are diminished in adult acute vaso-occlusive sickle cell crisis in the emergency department. Br J Haematol 2003, 120:532-534.
5. Lopez B., Davis-Moon L., Ballas S. Sequential nitric oxide measurements during the emergency department treatment of acute vasoocclusive sickle cell crisis. Am J Hematol 2000, 64:15-19.
6. Lopez B.L., Barnett J., Ballas S.K., et al. Nitric oxide metabolite levels in acute vaso-occlusive sickle-cell crisis. Acad Emerg Med 1996, 3:1098-1103.
7. Morris C.R. Mechanisms of vasculopathy in sickle cell disease and thalassemia. Hematology Am Soc Hematol Educ Program 2008, 2008:177-185.
8. Morris C.R., Gladwin M.T., Kato G. Nitric oxide and arginine dysregulation: a novel pathway to pulmonary hypertension in hemolytic disorders. Curr Mol Med 2008, 8:81-90.
9. Gornik H.L., Creager M.A. Arginine and endothelial and vascular health. JNutr 2004, 134(Suppl 10):2880S-2887S. [discussion: 95S].
10. Morris C.R., Morris S.M., Hagar W., et al. Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease?. Am J Respir Crit Care Med 2003, 168:63-69.
11. Morris C.R., Kuypers F.A., Lavrisha L., et al. Arandomized, placebo-control trial of arginine therapy for the treatment of children with sickle cell disease hospitalized with vaso-occlusive pain episodes. Haematologica 2013, 98:1375-1382.
12. Sher G.D., Olivieri N.G. Rapid healing of leg ulcers during arginine butyrate therapy in patients with sickle cell disease and thalassemia. Blood 1994, 84:2378-2380.
13. Koshy M, Askin M, McMahon L, etal, editors. Arginine butyrate in sickle cell leg ulcers: interim findings of a phase II trial. 24th Annual Meeting of the National Sickle Cell Disease Program. Philadelphia, PA, April 9-12, 2000.
14. McMahon L., Tamary H., Askin M., et al. Arandomized phase II trial of arginine butyrate with standard local therapy in refractory sickle cell leg ulcers. Br J Haematol 2010, 151(5):516-524.
15. Novelli E, Delaney K, Axelrod K, etal, editors. Arginine therapy in a patient with Hb-SS disease and refractory leg ulcers. Sickle Cell Disease Association of America Annual Convention. Baltimore, MD, September 25-29, 2012.
16. Moncada S., Higgs A. The L-arginine-nitric oxide pathway. NEngl J Med 1993, 329:2002-2012.
17. Palmer R.M., Ferrige A.G., Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nat Med 1987, 327:524-526.
18. Ignarro L.J. Heme-dependent activation of soluble guanylate cyclase by nitric oxide: regulation of enzyme activity by porphyrins and metalloporphyrins. Semin Hematol 1989, 26:63-76.
19. Kaul D.K., Hebbel R.P. Hypoxia/reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice. JClin Invest 2000, 106:411-420.
20. Hebbel R.P., Osarogiagbon K.D. The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy. Microcirculation 2004, 11:129-151.
21. Peng H.B., Spiecker M., Liao J. Inducible nitric oxide: an autoregulatory feedback inhibitor of vascular inflammation. JImmunol 1998, 161:1970-1976.
22. Reiter C.D., Gladwin M.T. An emerging role for nitric oxide in sickle cell disease vascular homeostasis and therapy. Curr Opin Hematol 2003, 10:99-107.
23. Gladwin M., Schechter A., Ognibene F., et al. Divergent nitric oxide bioavailability in men and women with sickle cell disease. Circulation 2003, 107:271-278.
24. Reiter C., Wang X., Tanus-Santos J., et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle cell disease. Nat Med 2002, 8:1383-1389.
25. Minneci P.C., Deans K.J., Zhi H., et al. Hemolysis-associated endothelial dysfunction mediated by accelerated NO inactivation by decompartmentalized oxyhemoglobin. JClin Invest 2005, 115(12):3409-3417.
26. Deonikar P., Kavdia M. Low micromolar intravascular cell-free hemoglobin concentration affects vascular NO bioavailability in sickle cell disease: a computational analysis. JAppl Physiol 2012, 112(8):1383-1392.
27. Omodeo-Sale F., Cortelezzi L., Vommaro Z., et al. Dysregulation of L-arginine metabolism and bioavailability associated to free plasma heme. Am J Physiol Cell Physiol 2010, 299(1):C148-C154.
28. Donadee C., Raat N.J., Kanias T., et al. Nitric oxide scavenging by red blood cell microparticles and cell-free hemoglobin as a mechanism for the red cell storage lesion. Circulation 2011, 124(4):465-476.
29. Baron D.M., Beloiartsev A., Nakagawa A., et al. Adverse effects of hemorrhagic shock resuscitation with stored blood are ameliorated by inhaled nitric oxide in lambs. Crit Care Med 2013, 41(11):2492-2501.
30. Hill A., Rother R.P., Wang X., et al. Effect of eculizumab on haemolysis-associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 2010, 149(3):414-425.
31. Yeo T.W., Lampah D.A., Gitawati R., et al. Impaired nitric oxide bioavailability and L-arginine reversible endothelial dysfunction in adults with falciparum malaria. JExp Med 2007, 204(11):2693-2704.
32. Morris S.M. Arginine: beyond protein. Am J Clin Nutr 2006, 83(2):508S-512S.
33. Hallemeesch M.M., Lamers W.H., Deutz N.E. Reduced arginine availability and nitric oxide production. Clin Nutr 2002, 21(4):273-279.
34. Kato G.J., Gladwin M.T., Steinberg M.H. Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev 2007, 21(1):37-47.
35. Kato G.J., McGowan V., Machado R.F., et al. Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood 2006, 107(6):2279-2285.
36. Cox S.E., Makani J., Komba A.N., et al. Global arginine bioavailability in Tanzanian sickle cell anaemia patients at steady-state: a nested case control study of deaths versus survivors. Br J Haematol 2011, 155(4):522-524.
37. Tripolt N.J., Meinitzer A., Eder M., et al. Multifactorial risk factor intervention in patients with type 2 diabetes improves arginine bioavailability ratios. Diabet Med 2012, 29(10):e365-e368.
38. Lara A., Khatri S.B., Wang Z., et al. Alterations of the arginine metabolome in asthma. Am J Respir Crit Care Med 2008, 178(7):673-681.
39. Morris C.R., Poljakovic M., Lavisha L., et al. Decreased arginine bioavailability and increased arginase activity in asthma. Am J Respir Crit Care Med 2004, 170:148-153.
40. Morris CR, Teehankee C, Kato G, etal, editors. Decreased arginine bioavailability contributes to the pathogenesis of pulmonary artery hypertension. American College of Cardiology Annual Meeting. Orlando (FL), March 6-9, 2005.
41. Morris C.R. New strategies for the treatment of pulmonary hypertension in sickle cell disease: the rationale for arginine therapy. Treat Respir Med 2006, 5(1):31-45.
42. Tang W.H., Wang Z., Cho L., et al. Diminished global arginine bioavailability and increased arginine catabolism as metabolic profile of increased cardiovascular risk. JAm Coll Cardiol 2009, 53(22):2061-2067.
43. Tang W.H., Shrestha K., Wang Z., et al. Diminished global arginine bioavailability as a metabolic defect in chronic systolic heart failure. JCard Fail 2013, 19(2):87-93.
44. Sourij H., Meinitzer A., Pilz S., et al. Arginine bioavailability ratios are associated with cardiovascular mortality in patients referred to coronary angiography. Atherosclerosis 2011, 218(1):220-225.
45. Wang Z., Tang W.H., Cho L., et al. Targeted metabolomic evaluation of arginine methylation and cardiovascular risks: potential mechanisms beyond nitric oxide synthase inhibition. Arterioscler Thromb Vasc Biol 2009, 29(9):1383-1391.
46. Morris S.M. Enzymes of arginine metabolism. JNutr 2004, 134:2743S-2747S.
47. Wu G., Morris S.M. Arginine metabolism: nitric oxide and beyond. Biochem J 1998, 336:1-17.
48. Stuehr D.J., Kwon N., Nathan C.F., et al. N-Hydroxyl-L-arginine is an intermediate in the biosynthesis of nitric oxide for L-arginine. JBiol Chem 1991, 266:6259-6263.
49. Hsu L.L., Champion H.C., Campbell-Lee S.A., et al. Hemolysis in sickle cell mice causes pulmonary hypertension due to global impairment in nitric oxide bioavailability. Blood 2007, 109:3088-3098.
50. Li H., Meininger C.J., Hawker J.R., et al. Regulatory role of arginase I and II in nitric oxide, polyamine, and proline syntheses in endothelial cells. Am J Physiol 2002, 282:R64-R69.
51. Durante W., Johnson F.K., Johnson R.A. Arginase: a critical regulator of nitric oxide synthesis and vascular function. Clin Exp Pharmacol Physiol 2007, 34(9):906-911.
52. Morris C.R., Kuypers F.A., Kato G.J., et al. Hemolysis-associated pulmonary hypertension in thalassemia. Ann N Y Acad Sci 2005, 1054:481-485.
53. Morris C.R., Vichinsky E., Singer S.T. Pulmonary hypertension in thalassemia: association with hemolysis, arginine metabolism dysregulation and a hypercoagulable state. Advances Pulmonary Hypertension 2007, 6:31-38.
54. Morris C.R. Asthma management: reinventing the wheel in sickle cell disease. Am J Hematol 2009, 84(4):234-241.
55. Morris C.R. Role of arginase in sickle cell lung disease and hemolytic anemias. Open Nitric Oxide J 2010, 2:41-54.
56. Messeri-Dreissig M.D., Hammermann R., Mossner J., et al. In rat alveolar macrophages lipopolysaccharides exert divergent effects on the transport of the cationic amino acids L-arginine and L-ornithine. Naunyn Schmiedbergs Arch Pharmacol 2000, 361:621-628.
57. Bogle R.G., Baydoun A.R., Pearson J.D., et al. L-arginine transport is increased in macrophages generating nitric oxide. Biochem J 1992, 284:15-18.
58. Hammermann R., Hirschmann J., Hey C., et al. Cationic proteins inhibit L-arginine uptake in rat alveolar macrophages and tracheal epithelial cells. Implications for nitric oxide synthesis. Am J Respir Cell Mol Biol 1999, 21:155-162.
59. Mendes Ribeiro A.C., Brunini T.M. L-arginine transport in disease. Curr Med Chem Cardiovasc Hematol Agents 2004, 2:123-131.
60. Meurs H., Schuurman F.E., Duyvendak M., et al. Deficiency of nitric oxide in polycation-induced airway hyperreactivity. Br J Pharmacol 1999, 126:559-562.
61. Yahata T., Nishimura Y., Maeda H., et al. Modulation of airway responsiveness by anionic and cationic polyelectrolyte substances. Eur J Pharmacol 2002, 434:71-79.
62. Gladwin M., Sachdev V., Jison M., et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. NEngl J Med 2004, 350:22-31.
63. De Castro L.M., Jonassaint J.C., Graham F.L., et al. Pulmonary hypertension associated with sickle cell disease: clinical and laboratory endpoints and disease outcomes. Am J Hematol 2008, 83(1):19-25.
64. Vallance P. The asymmetrical dimethylarginine/dimethylarginine dimethylaminohydrolase pathway in the regulation of nitric oxide generation. Clin Sci 2001, 100:159-160.
65. Kato G.J., Wang Z., Machado R.F., et al. Endogenous nitric oxide synthase inhibitors in sickle cell disease: abnormal levels and correlations with pulmonary hypertension, desaturation, haemolysis, organ dysfunction and death. Br J Haematol 2009, 145(4):506-513.
66. Schnog J.B., Teerlink T., van der Dijs F.P., et al. Plasma levels of asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, are elevated in sickle cell disease. Ann Hematol 2005, 84(5):282-286.
67. Landburg P.P., Teerlink T., Muskiet F.A., et al. Plasma concentrations of asymmetric dimethylarginine, an endogenous nitric oxide synthase inhibitor, are elevated in sickle cell patients but do not increase further during painful crisis. Am J Hematol 2008, 83(7):577-579.
68. Scott J.A., North M.L., Rafii M., et al. Asymmetric dimethylarginine is increased in asthma. Am J Respir Crit Care Med 2011, 184(7):779-785.
69. Riccioni G., Bucciarelli V., Verini M., et al. ADMA, SDMA, L-Arginine and nitric oxide in allergic pediatric bronchial asthma. JBiol Regul Homeost Agents 2012, 26(3):561-566.
70. Gorenflo M., Zheng C., Werle E., et al. Plasma levels of asymmetrical dimethyl-L-arginine in patients with congenital heart disease and pulmonary hypertension. JCardiovasc Pharmacol 2001, 37(4):489-492.
71. Kielstein J.T., Bode-Boger S.M., Hesse G., et al. Asymmetrical dimethylarginine in idiopathic pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol 2005, 25(7):1414-1418.
72. Millatt L.J., Whitley G.S., Li D., et al. Evidence for dysregulation of dimethylarginine dimethylaminohydrolase I in chronic hypoxia-induced pulmonary hypertension. Circulation 2003, 108(12):1493-1498.
73. Pullamsetti S., Kiss L., Ghofrani H.A., et al. Increased levels and reduced catabolism of asymmetric and symmetric dimethylarginines in pulmonary hypertension. FASEB J 2005, 19(9):1175-1177.
74. Perticone F., Sciacqua A., Maio R., et al. Asymmetric dimethylarginine, L-arginine, and endothelial dysfunction in essential hypertension. JAm Coll Cardiol 2005, 46(3):518-523.
75. Meinitzer A., Seelhorst U., Wellnitz B., et al. Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (the Ludwigshafen risk and cardiovascular health study). Clin Chem 2007, 53(2):273-283.
76. El-Shanshory M., Badraia I., Donia A., et al. Asymmetric dimethylarginine levels in children with sickle cell disease and its correlation to tricuspid regurgitant jet velocity. Eur J Haematol 2013, 91(1):55-61.
77. Sydow K., Munzel T. ADMA and oxidative stress. Atheroscler Suppl 2003, 4(4):41-51.
78. Morris C.R., Kuypers F.A., Larkin S., et al. Arginine therapy: a novel strategy to increase nitric oxide production in sickle cell disease. Br J Haematol 2000, 111:498-500.
79. Morris C.R., Vichinsky E.P., van Warmerdam J., et al. Hydroxyurea and arginine therapy: impact on nitric oxide production in sickle cell disease. JPediatr Hematol Oncol 2003, 25:629-634.
80. Sullivan K.J., Kissoon N., Sandler E., et al. Effect of oral arginine supplementation on exhaled nitric oxide concentration in sickle cell anemia and acute chest syndrome. JPediatr Hematol Oncol 2010, 32(7):e249-e258.
81. Styles L, Kuypers F, Kesler K, etal, editors. Arginine therapy does not benefit children with sickle cell anemia: results of the comprehensive sickle cell center multi-center study. 35th Convention of the National Sickle Cell Disease Program and the Sickle Cell Disease Association of America. Washington, DC, September 17-22, 2007.
82. Morris CR. Reduced global arginine bioavailability: a common mechanism of vasculopathy in sickle cell disease and pulmonary hypertension [e-letter]. Blood. Available at: Accessed April 22, 2010. http://bloodjournal.hematologylibrary.org/cgi/eletters/blood-2010-02-268193v1.
83. Maxwell A.J., Cooke J.P. Cardiovascular effects of L-arginine. Curr Opin Nephrol Hypertens 1998, 7:63-70.
84. Merimee T.J., Rabinowitz D., Riggs L., et al. Plasma growth hormone after arginine infusion. NEngl J Med 1967, 276:434-439.
85. Merimee T.J., Rabinowitz D., Fineberg S. Arginine-initiated release of human growth hormone. NEngl J Med 1969, 28:1434-1438.
86. Romero J., Suzuka S., Nagel R., et al. Arginine supplementation of sickle transgenic mice reduces red cell density and Gardos channel activity. Blood 2002, 99:1103-1108.
87. Sinden R.E., Barker G.C., Paton M.J., et al. Factors regulating natural transmission of Plasmodium berghei to the mosquito vector, and the cloning of a transmission-blocking immunogen. Parassitologia 1993, 35(Suppl):107-112.
88. Dasgupta T., Hebbel R.P., Kaul D.K. Protective effect of arginine on oxidative stress in transgenic sickle mouse models. Free Radic Biol Med 2006, 41(12):1771-1780.
89. Kaul D.K., Zhang X., Dasgupta T., et al. Arginine therapy of transgenic-knockout sickle mice improves microvascular function by reducing non-nitric oxide vasodilators, hemolysis, and oxidative stress. Am J Physiol Heart Circ Physiol 2008, 295(1):H39-H47.
90. Little J.A., Hauser K.P., Martyr S.E., et al. Hematologic, biochemical, and cardiopulmonary effects of L-arginine supplementation or phosphodiesterase 5 inhibition in patients with sickle cell disease who are on hydroxyurea therapy. Eur J Haematol 2009, 82(4):315-321.
91. Archer D.R., Stiles J.K., Newman G.W., et al. C-reactive protein and interleukin-6 are decreased in transgenic sickle cell mice fed a high protein diet. JNutr 2008, 138(6):1148-1152.
92. Gladwin M.T., Barst R.J., Castro O.L., et al. Pulmonary hypertension and NO in sickle cell. Blood 2010, 116(5):852-854.
93. Bunn H.F., Nathan D.G., Dover G.J., et al. Pulmonary hypertension and nitric oxide depletion in sickle cell disease. Blood 2010, 116(5):687-692.
94. Elias D.B., Barbosa M.C., Rocha L.B., et al. L-arginine as an adjuvant drug in the treatment of sickle cell anaemia. Br J Haematol 2013, 160(3):410-412.
95. Perrine S.P., Ginder G.D., Faller D.V., et al. Ashort-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders. NEngl J Med 1993, 328(2):81-86.
96. Sutton L.L., Castro O., Cross D.J., et al. Pulmonary hypertension in sickle cell disease. Am J Cardiol 1994, 74:626-628.
97. Sher G.D., Ginder G.D., Little J., et al. Extended therapy with intravenous arginine butyrate in patients with b-hemoglobinopathies. NEngl J Med 1995, 332:1606-1610.
98. Perrine S.P., Olivieri N.F., Faller D.V., et al. Butyrate derivatives. New agents for stimulating fetal globin production in the beta-globin disorders. Am J Pediatr Hematol Oncol 1994, 16:67-71.
99. Nagaya N., Uematsu M., Oya H., et al. Short-term oral administration of L-arginine improves hemodynamics and exercise capacity in patients with precapillary pulmonary hypertension. Am J Respir Crit Care Med 2001, 163:887-891.
100. Mehta S., Stewart D., Langleben D., et al. Short-term pulmonary vasodilation with L-arginine in pulmonary hypertension. Circulation 1995, 92:1539-1545.
101. McCaffrey M., Bose C., Reiter P., et al. Effect of L-arginine infusion on infants with persistent pulmonary hypertension of the newborn. Biol Neonate 1995, 67:240-243.
102. Surdacki A., Zmudka K., Bieron K., et al. Lack of beneficial effects of L-arginine infusion in primary pulmonary hypertension. Wien Klin Wochenschr 1994, 106:521-526.
103. Baudouin S.V., Bath P., Martin J.F., et al. L-arginine infusion has no effect on systemic haemodynamics in normal volunteers, or systemic and pulmonary haemodynamics in patients with elevated pulmonary vascular resistance. Br J Clin Pharmacol 1993, 36:45-49.
104. Farmakis D., Aessopos A. Pulmonary hypertension associated with hemoglobinopathies: prevalent but overlooked. Circulation 2011, 123(11):1227-1232.
105. Morris C.R., Vichinsky E.P. Pulmonary hypertension in thalassemia. Ann N Y Acad Sci 2010, 1202:205-213.
106. Gladwin M.T., Vichinsky E. Pulmonary complications of sickle cell disease. NEngl J Med 2008, 359(21):2254-2265.
107. Bachir D., Parent F., Hajji L., et al. Prospective multicentric survey on pulmonary hypertension (PH) in adults with sickle cell disease. Blood 2009, 114. [abstract 572].
108. Gladwin M.T. Prevalence, risk factors and mortality of pulmonary hypertension defined by right heart catheterization in patients with sickle cell disease. Expert Rev Hematol 2011, 4(6):593-596.
109. Parent F., Bachir D., Inamo J., et al. Ahemodynamic study of pulmonary hypertension in sickle cell disease. NEngl J Med 2011, 365(1):44-53.
110. Fonseca G.H., Souza R., Salemi V.C., et al. Pulmonary hypertension diagnosed by right heart catheterization in sickle cell disease. Eur Respir J 2012, 39(1):112-118.
111. Mehari A., Gladwin M.T., Tian X., et al. Mortality in adults with sickle cell disease and pulmonary hypertension. JAMA 2012, 307(12):1254-1256.
112. Machado R.F., Barst R.J., Yovetich N.A., et al. Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. Blood 2011, 118(4):855-864.
113. Morris C.R., Gladwin M.T. Pulmonary hypertension in sickle cell disease and thalassemia. Pulmonary circulation 2011, 271-287. Hodder Arnold, London. 3rd edition. A. Peacock, R. Naeije, L. Rubin (Eds.).
114. Barst R.J., Mubarak K.K., Machado R.F., et al. Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies. Br J Haematol 2010, 149(3):426-435.
115. Klings E, Machado R, Barst R, etal. Consensus-based guidelines for the diagnosis and treatment of pulmonary hypertension of sickle cell disease. Am J Respir Crit Care Med, in press.
116. Sutton M, Weinberg R, Padilla M, etal, editors. Development of pulmonary hypertension in sickle cell disease in spite of a response to hydroxyurea. 24th Annual Meeting of the National Sickle Cell Disease Program. Philadelphia, PA, April 9-12, 2000.
117. Xu W., Kaneko T.F., Zheng S., et al. Increased arginase II and decreased NO synthesis in endothelial cells of patients with pulmonary arterial hypertension. FASEB J 2004, 18:1746-1748.
118. Morris C.R., Kim H.Y., Wood J., et al. Sildenafil therapy in thalassemia patients with Doppler-defined risk of pulmonary hypertension. Haematologica 2013, 98(9):1359-1367.
119. Morris C.R. Vascular risk assessment in patients with sickle cell disease. Haematologica 2011, 96(1):1-5.
120. Hebbel R.P. Reconstructing sickle cell disease: a data-based analysis of the "hyperhemolysis paradigm" for pulmonary hypertension from the perspective of evidence-based medicine. Am J Hematol 2011, 86(2):123-154.
121. Kato G.J. Priapism in sickle-cell disease: a hematologist's perspective. JSex Med 2012, 9(1):70-78.
122. Nolan V.G., Wyszynski D.F., Farrer L.A., et al. Hemolysis-associated priapism in sickle cell disease. Blood 2005, 106(9):3264-3267.
123. Bialecki E.S., Bridges K.R. Sildenafil relieves priapism in patients with sickle cell disease. Am J Med 2002, 113(3):252.
124. Bivalacqua T.J., Musicki B., Hsu L.L., et al. Sildenafil citrate-restored eNOS and PDE5 regulation in sickle cell mouse penis prevents priapism via control of oxidative/nitrosative stress. PLoS One 2013, 8(7):e68028.
125. Bunn H.F. Pathogenesis and treatment of sickle cell disease. NEngl J Med 1997, 337(11):762-769.
126. Brousseau D.C., Owens P.L., Mosso A.L., et al. Acute care utilization and rehospitalizations for sickle cell disease. JAMA 2010, 303(13):1288-1294.
127. Barbul A., Rettura G., Levenson S.M., et al. Wound healing and thymotropic effects of arginine: a pituitary mechanism of action. Am J Clin Nutr 1983, 37:786-794.
128. Barbul A. Arginine: biochemistry, physiology and therapeutic implications. JPEN J Parenter Enteral Nutr 1986, 10:227-238.
129. McEvoy G. American Society of Health-System Pharmacists. 1996.
130. Hertz P., Richardson J. Arginine-induced hyperkalemia in renal failure patients. Arch Intern Med 1972, 130:778-780.
131. Medication error causes death of boy, 3. Florida Today. Oct 25, 2007.
132. Morris C., Ansari M., Lavrisha L., et al. Arginine therapy for vaso-occlusive pain episodes in sickle cell disease. Blood 2009, 114. [abstract 573].
133. Little J.A., McGowan V.R., Kato G.J., et al. Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review. Haematologica 2006, 91(8):1076-1083.
134. Berka V., Yeh H.C., Gao D., et al. Redox function of tetrahydrobiopterin and effect of L-arginine on oxygen binding in endothelial nitric oxide synthase. Biochemistry 2004, 43(41):13137-13148.
135. Wood K.C., Hebbel R.P., Lefer D.J., et al. Critical role of endothelial cell-derived nitric oxide synthase in sickle cell disease-induced microvascular dysfunction. Free Radic Biol Med 2006, 40(8):1443-1453.
136. Gladwin M.T., Kato G.J., Weiner D., et al. Nitric oxide for inhalation in the acute treatment of sickle cell pain crisis: a randomized controlled trial. JAMA 2011, 305(9):893-902.
137. Vichinsky E. Emerging 'A' therapies in hemoglobinopathies: agonists, antagonists, antioxidants, and arginine. Hematology Am Soc Hematol Educ Program 2012, 2012:271-275.
138. Solomons C., Hathaway W., Cotton E. L-arginine, the sickling phenomenon, and cystic fibrosis. Pediatrics 1972, 49:933.